Direct answer: AmnioAMP is a dehydrated human amniotic membrane allograft used as a wound covering and biologic barrier for partial- and full-thickness wounds. It is processed from donated placental amnion, stored at room temperature, and billed under HCPCS Q4250 (AmnioAMP-MP, per square centimeter) within the CMS skin-substitute framework. It contains no living cells after dehydration — its activity is associated with the retained extracellular matrix and matrix-bound signaling proteins.
AmnioAMP sits in the category wound centers most often ask about by name: amniotic membrane allografts. This overview consolidates what the product is, what it is made of, how it is handled and stored, how it is coded, and how it compares with the other allograft in the NextGen portfolio — with the evidence base cited throughout. It is written for wound care physicians, podiatrists, and wound-center medical directors evaluating or using amniotic membrane products.
What AmnioAMP is made of
AmnioAMP is derived from human amniotic membrane, the innermost layer of the placenta. The tissue is recovered from consented donors, screened and processed under tissue-bank standards (AATB-accredited recovery, donor eligibility per 21 CFR 1271 Subpart C), then decellularized and dehydrated. The result is a collagen-rich extracellular matrix sheet that retains structural proteins — collagen, fibronectin, laminin — together with matrix-bound growth factors and cytokines associated with tissue repair.
The biological characterization literature on dehydrated amniotic membrane allografts identifies retained PDGF-AA, bFGF, TGF-β1, EGF, and interleukins including IL-4, IL-6, IL-8, and IL-10, along with tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2, TIMP-4), in a sustained-release rather than bolus elution profile (PMID 32458591). Reviews of amniotic membrane adjuncts in wound healing describe the combined scaffold-plus-signaling profile as the basis for clinical use across chronic wound etiologies (PMID 30059334).
Because dehydration eliminates viable cells, AmnioAMP is an acellular matrix product. Preclinical work with dehydrated, aseptically processed amnion/chorion allografts demonstrates accelerated healing in delayed murine excisional wound models (PMID 33545130 is dHACA mouse-model data on the category; see also the mechanistic review PMID 36986608).
Product specifications at a glance
| Attribute | AmnioAMP-MP |
|---|---|
| Product category | Dehydrated human amniotic membrane allograft (HCT/P) |
| Tissue source | Donated placental amnion (consented, screened) |
| Format | Single-layer dehydrated membrane sheet, conformable |
| Viable cells | None (acellular after dehydration) |
| Storage | Room temperature; no freezer or dry-ice cold chain |
| Shelf life | Per manufacturer expiration dating on package |
| Orientation | Non-side-specific after rehydration per IFU; stromal (collagen-rich) surface conventionally placed toward the wound bed |
| HCPCS code | Q4250 (AmnioAMP-MP, per square centimeter) |
| Application CPT | 15271–15278 range (application to extremities/trunk etc., by site and first-additional sq cm) |
| Regulatory pathway | HCT/P under 21 CFR 1271 (Section 361); no device clearance claimed |
| Typical use | Adjunct after stalled standard care in chronic wounds |
Confirm current sizing, orientation, and expiration details against the manufacturer Instructions for Use supplied with each graft; specifications are controlled by the tissue processor and can change.
How AmnioAMP works in wound healing
Amniotic membrane allografts are used as an adjunct within standard wound care — not a replacement for debridement, offloading, compression, infection control, or glycemic management. The proposed mechanisms are threefold:
- Structural scaffold. The collagen-rich matrix provides a template for cell migration and granulation over the wound surface.
- Matrix-bound signaling. Retained growth factors and cytokines are released from the matrix over time rather than as a single bolus (PMID 32458591). Reviews position this sustained-elution characteristic as central to the membrane's role in chronic wounds, where prolonged signaling support is needed to re-establish repair (PMID 30059334).
- Protease modulation. The TIMP content is relevant to the chronic wound environment, where excess matrix metalloproteinase (MMP) activity degrades newly deposited matrix and perpetuates inflammation; contributing TIMPs may help rebalance the protease–antiprotease axis (PMID 32458591, PMID 30059334).
Angiogenic support has also been reported: human amniotic membrane promoted angiogenesis in an oxidative-stress chronic diabetic murine wound model (PMID 35293255).
Evidence framing: the mechanistic and preclinical data establish biologic plausibility for the category. Clinical outcomes should be evaluated from the randomized-trial literature on amniotic membrane products, summarized below — category-level evidence, not claims about AmnioAMP-specific trials.
Clinical applications and indications
AmnioAMP is applied to partial- and full-thickness acute and chronic wounds. Common settings include:
- Diabetic foot ulcers
- Venous leg ulcers
- Pressure injuries
- Burns and other partial-thickness skin losses
- Post-surgical and dehisced wounds
The randomized evidence base is strongest in diabetic foot ulcers. A systematic review and meta-analysis of RCTs in chronic DFUs reported that amniotic membrane plus standard of care achieved complete healing roughly 4 times more often at 6 weeks (RR 3.88) and about twice as often at 12 weeks (RR 2.01) versus standard care alone (PMID 32119765). A systematic review on rational use across indications cautions that trial heterogeneity and product variability mean results should inform, not dictate, product selection (PMID 33588807).
Regulatory note. AmnioAMP-MP is regulated as a human cells, tissues, and cellular and tissue-based product (HCT/P) under 21 CFR 1271 Section 361. No FDA device clearance is claimed for a wound-healing indication. Use is governed by the manufacturer's Instructions for Use and clinician judgment.
Storage and handling
AmnioAMP is dehydrated and stored at room temperature. It requires no freezer, dry ice, or thaw step, which removes cold-chain failure points that affect cryopreserved amniotic products and simplifies clinic inventory. Preparation at the point of use follows the Instructions for Use: rehydrate in sterile saline (typically 2–3 minutes), trim to overlap wound margins by 1–2 mm, place with the stromal side contacting the wound bed, and secure with a non-adherent primary dressing plus absorbent secondary layer. Offloading or pressure redistribution remains essential for lower-extremity wounds. The full team workflow is covered in the AmnioAMP application protocol.
HCPCS billing and coding
- Product code: Q4250 — AmnioAMP-MP, per square centimeter.
- Application codes: CPT 15271–15278 (application of skin substitute graft to the appropriate anatomic site; first and additional square centimeters as applicable).
- Framework: CMS skin-substitute billing rules govern site-of-service payment, packaged supply considerations, and MAC-level coverage. Prior-authorization and documentation requirements vary by payer and Medicare Administrative Contractor (MAC).
A practical coding and audit-defense walkthrough for amniotic membrane allografts, including 2026 flat-rate changes, is maintained in the HCPCS and CPT coding guide.
How AmnioAMP compares to Rampart DL Matrix
Both products in the NextGen portfolio are dehydrated, room-temperature-stored amniotic membrane allografts — neither requires cryopreservation. The practical differences are layer count and conformability:
| Attribute | AmnioAMP-MP | Rampart DL Matrix |
|---|---|---|
| Layers | Single-layer amniotic membrane | Dual-layer membrane construction |
| Handling | Conformable sheet; suits irregular surfaces | More controlled sheet-based handling |
| Storage | Room temperature | Room temperature |
| Best fit | Irregular or broader treatment zones | Predictable, uniform graft placement |
For a full side-by-side with clinical and workflow framing, see AmnioAMP vs Rampart: a comparison for wound care clinicians.
Application protocol summary
- Confirm wound-bed preparation: debridement of non-viable tissue, infection control, adequate perfusion assessment.
- Rehydrate the graft per IFU (sterile saline, ~2–3 minutes).
- Measure and trim to overlap wound margins by 1–2 mm.
- Place with stromal side to the wound bed; ensure full contact, no tenting.
- Secure with non-adherent primary + absorbent secondary dressing.
- Offload lower-extremity wounds; schedule follow-up per center protocol.
- Document wound measurements, graft lot number, and sq cm applied (needed for Q4250 billing).
The complete protocol, including team roles and quality review, is in the step-by-step application guide.
Frequently asked questions
What is AmnioAMP?
A dehydrated human amniotic membrane allograft used as a wound covering and biologic barrier for partial- and full-thickness wounds, processed to retain extracellular matrix and matrix-bound growth factors (PMID 32458591).
What is AmnioAMP made of?
Human amniotic membrane, the innermost layer of the placenta, recovered from consented, screened donors. After decellularization and dehydration it retains a collagen-rich extracellular matrix with matrix-bound growth factors and cytokines — including PDGF-AA, bFGF, TGF-β1, EGF, interleukins, and TIMPs (PMID 32458591).
Is AmnioAMP cryopreserved?
No. It is dehydrated and stored at room temperature — no freezer, dry ice, or thaw step.
Does AmnioAMP contain living cells?
No. Dehydration eliminates viable cells; the retained activity is associated with the acellular matrix and its bound signaling proteins (PMID 32458591, PMID 30059334).
What HCPCS code is used?
Q4250 (AmnioAMP-MP, per square centimeter), with CPT 15271–15278 for application. Coverage varies by MAC and payer.
How is AmnioAMP stored?
At room temperature. No frozen storage, cryopreservation, dry ice, or thaw step is required.
What wounds is it used for?
DFUs, VLUs, pressure injuries, burns, and post-surgical wounds — as an adjunct after standard care has stalled. Category-level RCT evidence is strongest in DFUs (PMID 32119765).
How is it applied?
Rehydrate, trim with 1–2 mm margin overlap, stromal side down, secure, offload. See the application protocol.
How does it differ from Rampart DL Matrix?
Single-layer conformable sheet vs dual-layer membrane construction; both dehydrated and room-temperature stored. Orientation and layer handling are compared in detail in the AmnioAMP vs Rampart guide.
Who makes AmnioAMP?
AmnioAMP-MP is distributed by NextGen Biologics USA. (Manufacturer disclosure: this site is operated by the distributor; evaluate the IFU for processor information.)
Key takeaways:
- AmnioAMP is a dehydrated human amniotic membrane allograft for wound care — not cryopreserved.
- It is stored at room temperature and rehydrated in sterile saline before application.
- HCPCS code Q4250 applies; CPT 15271–15278 covers the application procedure.
- Clinical applications include DFUs, VLUs, pressure injuries, burns, and post-surgical wounds.
- It provides a biologic barrier, ECM scaffold, and matrix-bound growth factors in a sustained-release profile.
Ready to evaluate AmnioAMP or Rampart in your wound center? Request samples or a clinical-affairs consultation.
References
- Moore MC, Bonvallet PP, Damaraju SM, et al. Biological characterization of dehydrated amniotic membrane allograft: Mechanisms of action and implications for wound care. J Biomed Mater Res Part B. 2020. PMID 32458591. https://pubmed.ncbi.nlm.nih.gov/32458591/
- Kogan S, Sood A, Granick MS. Amniotic Membrane Adjuncts and Clinical Applications in Wound Healing: A Review of the Literature. Wounds. 2018. PMID 30059334. https://pubmed.ncbi.nlm.nih.gov/30059334/
- Su YN, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials. Int Wound J. 2020. PMID 32119765. https://pubmed.ncbi.nlm.nih.gov/32119765/
- Lakmal K, et al. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021. PMID 33588807. https://pubmed.ncbi.nlm.nih.gov/33588807/
- Wu M, et al. Human Amniotic Membrane Promotes Angiogenesis in an Oxidative Stress Chronic Diabetic Murine Wound Model. Adv Wound Care. 2023. PMID 35293255. https://pubmed.ncbi.nlm.nih.gov/35293255/
- Fitriani N, et al. Application of Amniotic Membrane in Skin Regeneration. Pharmaceutics. 2023. PMID 36986608. https://pubmed.ncbi.nlm.nih.gov/36986608/
- Dolivo D, et al. A dehydrated, aseptically-processed human amnion/chorion allograft accelerates healing in a delayed murine excisional wound model. Exp Cell Res. 2021. PMID 33545130. https://pubmed.ncbi.nlm.nih.gov/33545130/
This overview is provided for clinician education and product evaluation. AmnioAMP and Rampart are human tissue products regulated under 21 CFR 1271. Product-specific labeling, Instructions for Use, and the current Medicare Administrative Contractor Local Coverage Determination govern clinical use and billing. Always follow the manufacturer's Instructions for Use and institutional protocols. NextGen Biologics USA distributes AmnioAMP-MP; this article is clinical education for healthcare professionals, not medical advice. Individual results vary; verify current coding, coverage, and IFU requirements before use.